RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End

Ultragenyx Pharmaceutical (RARE) and Mereo BioPharma (MREO) shares fell sharply in premarket trading after the companies announced that the Phase III Orbit study for UX143, their osteogenesis imperfecta treatment, will continue as planned until year-end 2025 for final analysis, rather than concluding early as hoped. While an independent Data Monitoring Committee found UX143's interim safety profile acceptable, recommending the study proceed, the extended timeline for data readout prompted a negative market reaction, signaling investor concern over prolonged development in this area with no currently approved treatments.

Analysis

Ultragenyx Pharmaceutical (RARE) and its partner Mereo BioPharma (MREO) experienced a significant premarket decline in their share prices following the announcement that their Phase III Orbit study of UX143 (setrusumab) for osteogenesis imperfecta (OI) will not conclude early. Instead, the trial will proceed to its originally planned final analysis by the end of 2025. The market's negative reaction stems directly from the deferred timeline for a potential data catalyst, as investors had hoped for an early stop based on overwhelming efficacy. However, a key mitigating factor is the positive interim safety review by the independent Data Monitoring Committee, which found UX143's safety profile to be acceptable and recommended the study continue without modification. This suggests the drug is not failing on safety, but the efficacy signal was not strong enough for an early halt. With no currently approved treatments for OI, a condition affecting an estimated 60,000 individuals in key markets, the commercial opportunity for a successful therapy remains substantial, though the path to market is now confirmed to be longer. Year-to-date, MREO's 16% loss significantly underperforms both RARE's 1.5% loss and the broader industry's 2% decline, indicating heightened sensitivity to this developmental setback.

Key Decisions for Investors

• Investors should adjust valuation models for RARE and MREO to reflect the delayed revenue timeline for UX143, with a final data readout now not expected until year-end 2025.
• The acceptable interim safety profile reduces the risk of an outright trial failure due to safety, shifting the primary investment risk to the demonstration of sufficient efficacy in the final analysis.
• Monitor the cash burn and financial runway of both companies, particularly Mereo BioPharma, as the extended development timeline will increase operational expenses before any potential commercialization.